FDA sees biotech generics many years off

03/26/2007 | Forbes

Generic versions of biotech drugs may be many years off, FDA deputy commissioner Janet Woodcock told a congressional panel. She said it could be a decade or more before the FDA has the science needed to safely approve biotech generics in the way copies of traditional drugs now are evaluated. The situation could be a plus for biotech firms that never have faced competition from generic versions of their drugs.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA